TP53 and cancer: While mutations in BRCA1/BRCA2 are commonly known as the primary drivers of homologous recombination deficiency (HRD), strong positive associations between the TP53 mutation ratio and HRD scores have been observed in TCGA pan-cancer analysis [57].